126 related articles for article (PubMed ID: 38247066)
1. Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB).
Komatsu S; Kawai M; Takada M; Nakayama T; Masuda N; Shiheido H; Cai Z; Huang YJ; Kawaguchi T; Tanizawa Y
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1283-1294. PubMed ID: 38247066
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
5. Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.
Sohn G; Ahn SH; Kim HJ; Son BH; Lee JW; Ko BS; Lee Y; Lee SB; Baek S
Cancer Res Treat; 2016 Oct; 48(4):1351-1362. PubMed ID: 27063654
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland.
Teerenhovi H; Tuominen S; Nurmi-Rantala S; Hemmilä P; Ellonen A
Oncologist; 2021 Aug; 26(8):e1372-e1380. PubMed ID: 33955109
[TBL] [Abstract][Full Text] [Related]
8. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
Nelson DR; Brown J; Morikawa A; Method M
PLoS One; 2022; 17(2):e0264637. PubMed ID: 35213669
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Gluz O; Kuemmel S; Nitz U; Braun M; Lüdtke-Heckenkamp K; von Schumann R; Darsow M; Forstbauer H; Potenberg J; Uleer C; Grischke EM; Aktas B; Schumacher C; Zu Eulenburg C; Kates R; Jóźwiak K; Graeser M; Wuerstlein R; Baehner R; Christgen M; Kreipe HH; Harbeck N
Ann Oncol; 2023 Jun; 34(6):531-542. PubMed ID: 37062416
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
13. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
15. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Chen Z; Ouyang Q; Wang Y; Wang J; Wang H; Wu X; Zhang P; Huang J; Zheng Y; Cao W; Shao X; Xie N; Tian C; Liang H; Wang C; Zhang Y; Ren D; Wang X
Front Oncol; 2022; 12():829693. PubMed ID: 35311126
[TBL] [Abstract][Full Text] [Related]
16. Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
Lee J; Park CS; Oh JH; Park IC; Seong MK; Noh WC; Kim HA
Ann Surg Treat Res; 2023 Jul; 105(1):31-36. PubMed ID: 37441320
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
18. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
19. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.
Tanaka K; Tokunaga E; Yamashita N; Taketani K; Akiyoshi S; Morita M; Maehara Y
Surg Today; 2014 Sep; 44(9):1678-84. PubMed ID: 24218007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
